Combinations of pyrazole kinase inhibitors
The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R 1 -A-NR 4 —; A is a bond, C═O, NR g (C═O) or O(C═O) wherein R g is hydrogen or C 1-4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from fluorine, hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; C 1-4 alkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).
1. A combination comprising a proteasome inhibitor and a compound the formula (VIb):
or salts or tautomers or N-oxides thereof;
wherein R 20 is selected from hydrogen and methyl;
R 21a is selected from fluorine and chlorine; and
R 22a is selected from fluorine, chlorine and methoxy.
2. A combination according to claim 1 wherein the compound of the formula (VIb) is 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide or a salt thereof.
3. A combination according to claim 2 wherein the combination comprises a salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide formed with methanesulphonic acid.
4. A combination according to claim 1 wherein the proteasome inhibitor and compound of formula (VIb) are physically associated.
5. The combination of claim 1 wherein the proteasome inhibitor and compound of formula (VIb) are non-physically associated.
6. A method of inhibiting tumour growth in a mammal, which method comprises administering to the mammal an effective tumour growth-inhibiting amount of a combination according to claim 1 .
7. A method for treating or managing cancer in a patient suffering from, or being at risk of suffering from a cancer, said method comprising administering to said patient a therapeutically effective amount of a combination according to claim 1 .
8. A method of enhancing or potentiating the response rate in a patient suffering from a cancer where the patient is being treated with a cytotoxic compound or signalling inhibitor, or an ancillary agent, or two or more further anti-cancer agents, which method comprises administering to the patient, in combination with the cytotoxic compound or signalling inhibitor, or an ancillary agent, or two or more further anti-cancer agents, a combination as defined in claim 1 .
9. A combination according to claim 1 wherein the proteasome inhibitor is bortezimib.
10. A combination according to claim 1 wherein the combination further includes an additional agent selected from erythropoietin (EPO), granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-colony stimulating factor (G-CSF), zoledronate, pamidronate, ibandronate, dexamethazone, prednisone, prednisolone, leucovorin, folinic acid and megestrol acetate.
11. A combination according to claim 2 wherein the proteasome inhibitor and compound of formula (VIb) are physically associated.
12. The combination of claim 2 wherein the proteasome inhibitor and compound of formula (VIb) are non-physically associated.
13. A combination according to claim 3 wherein the proteasome inhibitor and the salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide are physically associated.
14. The combination of claim 3 wherein the proteasome inhibitor and the salt of 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide are non-physically associated.
15. A combination according to claim 2 wherein the proteasome inhibitor is bortezimib.
16. A combination according to claim 3 wherein the proteasome inhibitor is bortezimib.
17. A combination according to claim 4 wherein the proteasome inhibitor is bortezimib.
18. A combination according to claim 5 wherein the proteasome inhibitor is bortezimib.
19. A method of inhibiting tumour growth in a mammal, which method comprises administering to the mammal an effective tumour growth-inhibiting amount of a combination according to claim 2 .
20. A method of inhibiting tumour growth in a mammal, which method comprises administering to the mammal an effective tumour growth-inhibiting amount of a combination according to claim 3 .
21. A method for treating or managing cancer in a patient suffering from, or being at risk of suffering from a cancer, said method comprising administering to said patient a therapeutically effective amount of a combination according to claim 2 .
22. A method for treating or managing cancer in a patient suffering from, or being at risk of suffering from a cancer, said method comprising administering to said patient a therapeutically effective amount of a combination according to claim 3 .